Orby.co

Orby.co operates at the intersection of neurotechnology, clinical rehabilitation, medical devices, and digital health. Its Ortech platform is described as combining adaptive, non-invasive electrical stimulation with AI for movement rehabilitation and pain relief, including use cases involving neurological and musculoskeletal motor deficits. The company also describes nervous-system modulation as a way to support functional recovery and autonomy. This gives it a clinical-device orientation rather than a profile centered solely on general-purpose wellness software. However, the available company information does not identify comparable businesses or name direct competitors, so a reliable competitor-by-competitor comparison is not possible. Its $5 million angel round and four named investors indicate early-stage financing, while the reported 1–10 employee band points to a small organization. Its position should therefore be assessed as an early-stage clinical neurotechnology venture, not as an established medical-device incumbent.

Orby.co was founded in 2022 and has recorded one disclosed funding round: a $5 million angel round announced on Jun 23, 2024. The round included four investors—Charles Krieck, Paulo Carvao, Guilherme Chapiewski, and Ricardo Marino—and marks the clearest measurable financing inflection point in the company’s trajectory. The company’s product focus is Ortech, an AI-driven platform for non-invasive electrical stimulation in movement rehabilitation and pain relief. An R$80,000 BNDES Garagem competition prize, dated Jan 1, 2025, represents a further recognition milestone. By 2026, Orby.co was attracting attention for applying AI to movement recovery, and its company information indicates hiring activity across R&D, clinical, engineering, AI, regulatory, and operations roles. That hiring breadth suggests plans to build capabilities spanning product development and clinical execution, although the reported employee band remains 1–10 and current listed positions total two.